

DAFTAR PUSTAKA

1. World Health Organization (WHO). Tuberculosis [Internet]. WHO Website. 2024 [cited 2024 Nov 28]. Available from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>
2. Di K, Bengkulu K. Analisis Beban Ekonomi Dan Dampak Karena Tuberculosis Terhadap Kesejahteraan Di Kota Bengkulu. CHMK Heal J. 2020;4.
3. Perhimpunan Dokter Paru Indonesia. Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Vol. 001, Perhimpunan Dokter Paru Indonesia. 2021. 1–78 p.
4. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan. Petunjuk teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. In 2020. p. 218.
5. Mirzayev F, Viney K, Linh NN, Gonzalez-angulo L, Gegia M, Jaramillo E, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update Fuad. Cross Mark [Internet]. 2021; Available from: <http://dx.doi.org/10.1183/13993003.03300-2020>
6. World Health Organization (WHO). Global tuberculosis report 2024. 2024.
7. World Health Organization (WHO). Tuberculosis in South-East Asia Region [Internet]. WHO Website. 2024 [cited 2025 Mar 1]. Available from: <https://www.who.int/southeastasia/health-topics/tuberculosis>
8. Kementerian Kesehatan Indonesia. Profil Kesehatan Indonesia Tahun 2023 [Internet]. 2024. 100 p. Available from: <https://www.kemkes.go.id/id/profil-kesehatan-indonesia-2023>
9. BPS. Dalam Angka Dalam Angka. In: Kota Kediri Dalam Angka. 2018. p. 1–68.
10. Riset Kesehatan Dasar (Riskesdas). Laporan Riskesdas 2018 Nasional.pdf [Internet]. Lembaga Penerbit Balitbangkes. 2018. p. hal 156. Available from: [https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan Riskesdas 2018 Nasional.pdf](https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan_Riskesdas_2018_Nasional.pdf)
11. Zulfa Ayuningsih TYMW. Faktor yang Berhubungan dengan Kematian Pasien TB MDR Selama Masa Pengobatan di Indonesia Tahun 2015-2017. Pro Heal J Ilm Kesehat. 2019;1(2):1–46.

12. Chung-delgado K, Guillen-bravo S, Revilla-montag A, Bernabe-ortiz A. Mortality among MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors. PLoS One [Internet]. 2015;1–10. Available from: <https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0119332&type=printable>
13. Marine BT, Agago MA, Zewde MG. Time to death and its associated factors among tuberculosis patients undergoing directly observed therapy at Butajira General Hospital: using accelerated failure time model. BMC Public Health. 2025;
14. Usman, Abubakar, Doguwa, Sani I., Sadiq, Ibrahim A. Akor A. Exploring Accelerated Failure Time Models for Tuberculosis Survival: Log-Logistic and Weibull Survival Regression Model. J Sci Res Rev. 2025;2(1):27–36.
15. Kassie G, Gezahegn E, Endazenawe G, Shitemaw T, Negash Z, Dessu S. Survival status and risk factors for mortality among multidrug-resistant tuberculosis patients in Addis Ababa, Ethiopia: A retrospective follow-up study. J Clin Tuberc Other Mycobact Dis [Internet]. 2023;33(September):100398. Available from: <https://doi.org/10.1016/j.jctube.2023.100398>
16. Feng Z, Liao M, Zhang L. Sex differences in disease: sex chromosome and immunity. J Transl Med [Internet]. 2024; Available from: <https://doi.org/10.1186/s12967-024-05990-2>
17. Kubjane M, Cornell M, Osman M, Boulle A, Johnson LF. Drivers of sex differences in the South African adult tuberculosis incidence and mortality trends, 1990 – 2019. Sci Rep [Internet]. 2023;1–11. Available from: <https://doi.org/10.1038/s41598-023-36432-6>
18. Iradukunda A, Getnet F, Odjidja EN. Tuberculosis mortality and drug resistance among patients under TB treatment before and during COVID - 19 in Burundi: a case – control study. BMC Infect Dis [Internet]. 2025; Available from: <https://doi.org/10.1186/s12879-025-11093-0>
19. Azmiardi A. The Relationship between Age, Employment Status, Gender, Linezolid Use, and HIV Status on the Survival Duration of Short-Term Treated MDR-TB Patients. Univ Mulawarman. 2024;2024.
20. Yamini RR, R AK, Mugesh D, Kr S. Social Factors in The Fight Against

- Multidrug-Resistant Tuberculosis : A Case Control Study. Eur J Cardiovasc Med. 2024;14(06):138–43.
21. Roza RR. Survival Analysis dan Prediktor Keparahan Klinis pada Pasien Multi-Drug Resistance Tuberculosis (MDR-TB) di Rumah Sakit Umum Pusat Persahabatan, Jakarta Ro Rabian Rein Roza Tampubolon, dr. Vicka Oktaria, MPH, Ph.D.; dr. Ika Trisnawati, M.Sc., Sp.PD-KP; DR. Univ Gajah Mada. 2024;
 22. Anderson K, Pietersen E, Shepherd BE, Bian A, Dheda K, Warren R, et al. High mortality among patients hospitalized for drug- resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. HIV Med. 2022;(April):1085–97.
 23. Yoseph A, Arega A, Shume T, Tucha M, Debessa T, Birhanu B. The Quality of the Structural Domain of Tuberculosis Services at Public Health Facilities in Sidama Region , Southern Ethiopia : An Institution-Based Cross- Sectional Study Design. Preprints.org. 2024;
 24. Surya A, Setyaningsih B, Nasution HS, Parwati CG, Yuzwar YE, Osberg M, et al. Quality Tuberculosis Care in Indonesia : Using Patient Pathway Analysis to Optimize Public – Private Collaboration. J Infect Dis Suppl. 2017;216(Suppl 7).
 25. Province S, Mutembo S, Mutanga JN, Musokotwane K, Kanene C, Dobbin K, et al. Urban-rural disparities in treatment *outcomes* among recurrent TB cases in Southern Province, Zambia. BMC Infect Dis. 2019;1–8.
 26. Nicholson TJ, Hoddinott G, Seddon JA, Claassens MM, Zalm MM Van Der, Lopez E, et al. A systematic review of risk factors for mortality among tuberculosis patients in South Africa. Syst Rev [Internet]. 2023;1–16. Available from: <https://doi.org/10.1186/s13643-023-02175-8>
 27. Kementrian Kesehatan Republik Indonesia. Petunjuk Teknis Penggunaan Sistem Informasi Tuberkulosis (SITB). 2023;
 28. Lyon SM, Rossman MD. Pulmonary Tuberculosis. 2017;5(1):1–13.
 29. Masriadi, S.KM., S.Pd.I., S.Kg., M.Kes. M. Epidemiologi Penyakit Menular. 2nd ed. Depok: RajaGrafindo Persada; 2017. 392 p.
 30. Ummah MS. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. In: Kementerian Kesehatan Republik Indonesia [Internet]. Jakarta; 2020. p. 1–139. Available from: <https://www.tbindonesia.or.id/wp->

content/uploads/2021/06/UMUM_PNPK_revisi.pdf

31. Carlos A, Lemos M, Dias E. Special article Multidrug-resistant tuberculosis. *Brazilian J Infect Dis* [Internet]. 2013;17(2):239–46. Available from: <http://dx.doi.org/10.1016/j.bjid.2013.01.007>
32. World Health Organization (WHO). Global Tuberculosis Report 2019. WHO Web; 2019.
33. Son E, Choi H, Mok J, Kang YA, Jeong D, Jeon D. Timing and predictors of death during treatment in patients with multidrug / rifampin-resistant tuberculosis in South Korea. *KJIM*. 2024;640–9.
34. Kemenkes RI. Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024. *Pertem Konsolidasi Nas Penyusunan STRANAS TB*. 2020;135.
35. Kizito E, Musaazi J, Mutesasira K, Twinomugisha F, Namwanje H, Kiyemba T, et al. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study. *BMC Infect Dis*. 2021;1–7.
36. Gamtesa F, Id AA. Predictors of mortality in patients with drug- resistant tuberculosis : A systematic review and meta-analysis. *PLoS One* [Internet]. 2021;1–24. Available from: <http://dx.doi.org/10.1371/journal.pone.0253848>
37. Veeken LD, Kulsum ID, Lestari BW, Santoso P, Soetedjo NNM, Koesoemadinata RC, et al. High Rates of Mortality During Drug-Resistant Tuberculosis Treatment Among Individuals With Diabetes Mellitus and Low Body Mass Index. *Open Forum Infect Dis* [Internet]. 2022;12(7):1–9. Available from: <https://doi.org/10.1093/ofid/ofaf344>
38. Rokani J, Id B, Kalyango JN, Baluku JB, Katuramu R, Ssendikwanawa E, et al. Mortality rate and associated factors among patients co-infected with drug resistant tuberculosis / HIV at Mulago National Referral Hospital , Uganda , a retrospective cohort study. *PLOS Glob public Heal* [Internet]. 2023;1–15. Available from: <http://dx.doi.org/10.1371/journal.pgph.0001020>
39. Mrema G, Hussein A, Magoge W, Mmbaga V, Balama R, Nkiligi E. Predictors of mortality among multidrug - resistant tuberculosis patients after decentralization of services in Tanzania from 2017 to 2019 : retrospective cohort study [Internet]. *Bulletin of the National Research Centre*. Springer Berlin Heidelberg; 2024. Available from: <https://doi.org/10.1186/s42269-024-01235-w>

40. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014.
41. Adamu AL, Aliyu MH, Galadanci NA, Musa BM, Lawan UM, Bashir U, et al. The impact of rural residence and HIV infection on poor tuberculosis treatment *outcomes* in a large urban hospital : a retrospective cohort analysis. *Int J Equity Health*. 2018;1–11.
42. Ranganathan P, Deo V, Pramesh CS. Time - to - *Event* analysis. *Perspect Clin Res* [Internet]. 2025; Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12048091/pdf/PCR-16-102.pdf>
43. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies : an empirical comparison of models that directly estimate the prevalence ratio. *BMC Public Health*. 2003;13:1–13.
44. Kusumawardhani GE, Santi VM. Analisis Survival dengan Model Regresi pada Data Tersensor Berdistribusi. *J Stat dan Apl* [Internet]. 2018;2(2):28–35. Available from: <https://journal.unj.ac.id/unj/index.php/statistika/article/view/10338/6666>
45. Hill C, Carolina N. Median Survival or Mean Survival : Which Measure Is the Most Appropriate for Patients , Physicians , and Policymakers ? *Oncologist* [Internet]. 2019;1469–78. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6853128/pdf/onco13022.pdf>
46. Crowther MJ, Royston P, Clements M. A flexible parametric accelerated failure time model and the extension to time-dependent *acceleration factors*. *Biostatistics*. 2023;811–31.
47. Bukundi EM, Mhimbira F, Kishimba R, Kondo Z, Moshiri C. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Mortality and associated factors among adult patients on tuberculosis treatment in Tanzania : A retrospective cohort study. *J Clin Tuberc Other Mycobact Dis* [Internet]. 2021;24:100263. Available from: <https://doi.org/10.1016/j.jctube.2021.100263>
48. Baku O, Definisi K. Statistik bidang sosial.
49. Pesona Dessritina, Dien Gusta Anggraini Nursal S. Survival Analysis of Multi-Drug Resistant Tuberculosis Patients in North Sumatra. *J Kesehat*. 2023;3:133–41.
50. Badan Pusat Statistik. Klasifikasi Desa Perkotaan dan Perdesaan di Indonesia 2020 [Internet]. BPS Website; 2021. xiv+457. Available from:

<https://disparbud.bandungkab.go.id/>

51. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar J-W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. *J Infect*. 2018 Dec;77(6):469–78.
52. Prihatiningsih S, Fajar JK, Tamara F, Mahendra AI, Rizqiansyah CY, Adianingsih OR, et al. Risk factors of tuberculosis infection among health care workers: A meta-analysis. *Indian J Tuberc* [Internet]. 2020;67(1):121–9. Available from: <https://www.sciencedirect.com/science/article/pii/S0019570719303063>
53. Mahendradhata Y, Ahmad RA, Lefèvre P, Boelaert M, Stuyft P Van Der. Barriers for introducing HIV testing among tuberculosis patients in Jogjakarta , Indonesia : a qualitative study. *BMC Public Health*. 2008;10:1–10.
54. RI KK. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. 2024.
55. Izhar MD, Butar M, Hidayati F, Ruwayda R. Predictors and health-related quality of life with short form-36 for multidrug-resistant tuberculosis patients in Jambi , Indonesia : A case-control study. *Clin Epidemiol Glob Heal* [Internet]. 2021;12(June):100872. Available from: <https://doi.org/10.1016/j.cegh.2021.100872>
56. Teramaj Wongel Wotale, Abiyot Negash Terefe JAF. Modeling Time to Death of Patients with Multidrug-Resistant Tuberculosis at Saint Peter’s Specialized Hospital. *J Res Health Sci*. 2021;21(2).
57. Muluneh MA, Zeru AB, Derseh BT, Kebede AM. Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter ’ s Specialized Hospital , Addis Ababa , Ethiopia. *Can J Infect Dis Med Microbiol*. 2021;2021.
58. Tola H, Mansournia MA. National treatment *outcome* and predictors of death and treatment failure in multidrug- - resistant tuberculosis in Ethiopia : a 10- - year retrospective cohort study. *BMJ Open*. 2021;1–9.
59. Asokan S. Immune issues in elderly with TB. *Indian J Tuberc* [Internet]. 2022;69:S241–5. Available from: <https://www.sciencedirect.com/science/article/pii/S001957072200141X>
60. Olmo-font M. Tuberculosis in an Aging World. *MDPI*. 2022;1–13.
61. Ault R, Dwivedi V, Koivisto E, Nagy J, Miller K, Nagendran K, et al. Altered

monocyte phenotypes but not impaired peripheral T cell immunity may explain susceptibility of the elderly to develop tuberculosis. *Exp Gerontol* [Internet]. 2018;111:35–44. Available from: <https://www.sciencedirect.com/science/article/pii/S0531556518302870>

62. Piergallini TJ, Turner J, Antonio S. Tuberculosis in the elderly: Why inflammation matters Tucker. *HHS Public Access*. 2019;32–9.
63. Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S. Predictors of unsuccessful interim treatment *outcomes* of multidrug resistant tuberculosis patients. *BMC Infect Dis*. 2017;1–12.
64. Gayoso R, Dalcolmo M, Ueleres J, Barreira D. Predictors of mortality in multidrug-resistant tuberculosis patients from Brazilian reference centers , 2005 to 2012. *Brazilian J Infect Dis* [Internet]. 2018;22(4):305–10. Available from: <http://dx.doi.org/10.1016/j.bjid.2018.07.002>
65. Thomas BE, Thiruvengadam K, Rani S, Kadam D, Ovung S, Sivakumar S, et al. Smoking , alcohol use disorder and tuberculosis treatment *outcomes* : A dual co- morbidity burden that cannot be ignored. *PLoS One*. 2019;129:1–12.
66. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. *BMC Public Health*. 2008;12.
67. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M. The Social Determinants of Tuberculosis : From Evidence to Action. *Fram Heal Matters*. 2011;101(4):654–62.
68. CDC. Tuberculosis (TB) [Internet]. CDC Website. 2025 [cited 2026 Apr 1]. Available from: <https://www.cdc.gov/tb/health-equity/index.html>
69. Ali HML, Elfiyunai NN, Suryawanto N, Siauta VA. Hubungan Sosial Support terhadap Kepatuhan Pengobatan Pasien TB di Wilayah Kerja UUPTD Puskesmas Banggai. *J Pendidik Tambusai* [Internet]. 2023 Nov 28;7(3 SE-Articles of Research):26870–7. Available from: <https://jptam.org/index.php/jptam/article/view/10961>
70. Ismah Z, Sintia A, Nurjanah D, Sri M, Dalimunthe R. HUBUNGAN PEKERJAAN YANG BERESIKO TERINFEKSI TB : ANALISIS DATA PASIEN DI UPTD RS KHUSUS PARU PEMPROVSU 2020 - AGUSTUS 2024. *PREPOTIF J Kesehat Masy*. 2024;8(3):6905–14.
71. Zheng Z, Nehl EJ, Zhou C, Li J, Xie Z, Zhou Z, et al. Insufficient tuberculosis treatment leads to earlier and higher mortality in individuals co-infected with

- HIV in southern China : a cohort study. BMC Infect Dis. 2020;1–10.
72. Lelisho ME, Wotale TW, Tareke SA, Alemu BD, Hassen SS, Yemane DM. Survival rate and predictors of mortality among TB / HIV co - infected adult patients : retrospective cohort study. Sci Rep [Internet]. 2022;1–11. Available from: <https://doi.org/10.1038/s41598-022-23316-4>
73. Yusria A, Rintiswati N, Sumardi. Factors Associated With Tuberculosis Treatment Success Among Human Immunodeficiency Virus - Tuberculosis (Hiv-Tb) in H. Adam Malik General Hospital, Medan. Trop Med J. 2018;4(1):16–24.
74. World Health Organization (WHO). WHO consolidated guidelines on tuberculosis Module 4: Treatment. WHO Web; 2022. 60 p.
75. World Health Organization (WHO). Tuberculosis Care TREATMENT Endorsements : WHO Web; 2025. 60 p.
76. World Health Organization (WHO). Public-Private Mix For TB PrEventation And Care A Roadmap [Internet]. WHO Web; 2020. 36 p. Available from: <https://iris.who.int/server/api/core/bitstreams/d5facafd-b1b8-4b04-9759-2a0511d23069/content>
77. World Health Organization (WHO). WHO guideline on health workforce development , attraction , recruitment and retention in rural and remote areas [Internet]. National Library Of Medicine Web; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570763/pdf/Bookshelf_NBK570763.pdf
78. Health W, Regional O. Rural poverty and health systems in the WHO European Region.
79. World Health Organization (WHO). Global Tuberculosis Report 2021 [Internet]. WHO Web; 2021. 57 p. Available from: <https://www.who.int/publications/i/item/9789240037021>